[A24-22] Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V

Last updated 15.05.2024

Project no.:
A24-22

Commission:
Commission awarded on 07.02.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated

Result of dossier assessment:
  • Patients with treatment-naive mCRPC without HRR mutation: hint of lesser benefit
  • Patients with treatment-naive mCRPC with HRR mutation: added benefit not proven
  • Patients with pretreated mCRPC: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://dx.doi.org/10.60584/A24-22

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form